A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Phase 2 Withdrawn
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Phase 1 Withdrawn
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Phase 2 Withdrawn
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1/2 Withdrawn
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Phase 1/2 Withdrawn
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
Phase 1/2 Withdrawn
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Phase 2 Withdrawn
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
Phase 2 Withdrawn
IMMUNOX
Phase 2 Withdrawn
Study of FMT Combined With Nivolumab in Gastric Cancer
Phase NA Withdrawn
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
Phase 1/2 Withdrawn
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Phase 2 Withdrawn
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Phase 2/3 Withdrawn
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Phase 2 Withdrawn